Recerca

Àrea 5

Hemoteràpia-Hemostàsia

Articles de l'any 2010
Original

Originals publicats: 22

Factor d'impacte: mitjana: 4.27, total: 93.91

  • Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

    Cervantes F, Lopez-Garrido P, Montero MI, Jonte F, Martinez J, Hernandez-Boluda JC, Calbacho M, Sureda A, Perez-Rus G, Nieto JB, Perez-Lopez C, Roman-Gomez J, Gonzalez M, Pereira A, Colomer D
    HAEMATOL-HEMATOL J. 2010; 95: 1317-1324. IF: 6.416

  • Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation

    DeLarrea CF, Martinez C, Gaya A, Lopez-Guillermo A, Rovira M, Fernandez-Aviles F, Lozano M, Bosch F, Esteve J, Nomdedeu B, Montserrat E, Carreras E
    ANN ONCOL. 2010; 21: 1211-1216. IF: 5.647

  • Association study between polymorphims in GAS6-TAM genes and carotid atherosclerosis

    Hurtado B, Abasolo N, Munoz X, Garcia N, Benavente Y, Rubio F, DeFrutos PG, Krupinski J, Sala N
    THROMB HAEMOSTASIS. 2010; 104: 592-598. IF: 4.451

  • Polymorphisms in platelet glycoproteins Ia and IIIa are associated with arterial thrombosis and carotid atherosclerosis in type 2 diabetes

    Pellitero S, Reverter JL, Tassies D, Pizarro E, Monteagudo J, Salinas I, Aguilera E, Sanmarti A, Reverter JC
    THROMB HAEMOSTASIS. 2010; 103: 630-637. IF: 4.451

  • Hormonal responses to the 5-HT1A agonist buspirone in remitted endogenous depressive patients after long-term imipramine treatment

    Gomez-Gil E, Navines R, DeOsaba MJM, Diaz-Ricart M, Escolar G, Salamero M, Martin-Santos R, Galan A, Gasto C
    PSYCHONEUROENDOCRINO. 2010; 35: 481-489. IF: 4.194

Editorials

Editorials publicades: 2

Factor d'impacte: mitjana: 3.96, total: 7.91

  • GAS6 in systemic inflammatory diseases: with and without infection

    Hurtado B, DeFrutos PG
    CRIT CARE. 2010; 14: 0-0. IF: 4.931

  • Erythrophagocytosis in cold agglutinin disease

    Beya MD, Pereira A, Merino A
    TRANSFUSION. 2010; 50: 2310-2310. IF: 2.982

Multicèntrics

Multicèntrics publicats: 1

Factor d'impacte: mitjana: 2.98, total: 2.98

  • A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

    Cazenave JP, Follea G, Bardiaux L, Boiron JM, Lafeuillade B, Debost M, Lioure B, Harousseau JL, Tabrizi R, Cahn JY, Michallet M, Ambruso D, Schots R, Tissot JD, Sensebe L, Kondo T, Mccullough J, Rebulla P, Escolar G, Mintz P, Heddle NM, Goodrich RP, Bruhwyler J, Le C, Cook RJ, Stouch B
    TRANSFUSION. 2010; 50: 2362-2375. IF: 2.982

Més articles